Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 161-169 , June 2003

Radical radiotherapy for prostate cancer

  • C.C Parker

      Affiliations

    • Corresponding Author InformationCorrespondence to: C.C. Parker, Academic Radiotherapy, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    • ,
  • D.P Dearnaley

References 

  1. Dearnaley DP, Khoo VS, Norman AR, et al.  Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet. 1999;353(9149):267–272
  2. Zelefsky MJ, Fuks Z, Hunt M, et al.  High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int. J. Radiat. Oncol. Biol. Phys. 2002;53(5):1111–1116
  3. Nutting CM, Convery DJ, Cosgrove VP, et al.  Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2000;48(3):649–656
  4. Nutting CM, Corbishley CM, Sanchez-Nieto B, et al.  Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. Br. J. Radiol. 2002;75(890):151–161
  5. Khoo VS, Padhani AR, Tanner SF, et al.  Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. Br. J. Radiol. 1999;72(858):590–597
  6. Kagawa K, Lee WR, Schultheiss TE, et al.  Initial clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1997;38(2):319–325
  7. Padhani AR, Khoo VS, Suckling J, et al.  Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int. J. Radiat. Oncol. Biol. Phys. 1999;44(3):525–533
  8. Morr J, DiPetrillo T, Tsai JS, et al.  Implementation and utility of a daily ultrasound-based localization system with intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002;53(5):1124–1129
  9. Wu J, Haycocks T, Alasti H, et al.  Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother. Oncol. 2001;61(2):127–133
  10. Litzenberg D, Dawson LA, Sandler H, et al.  Daily prostate targeting using implanted radiopaque markers. Int. J. Radiat. Oncol. Biol. Phys. 2002;52(3):699–703
  11. Huang E, Dong L, Chandra A, et al.  Intrafraction prostate motion during IMRT for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002;53(2):261–268
  12. Vicini FA, Abner A, Baglan KL, et al.  Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better. Int. J. Radiat. Oncol. Biol. Phys. 2001;51(5):1200–1208
  13. Jhaveri FM, Klein EA, Kupelian PA, et al.  Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J. Clin. Oncol. 1999;17(10):3167–3172
  14. Smith EB, Frierson HF, Mills SE, et al.  Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading. Cancer. 2002;94(8):2282–2287
  15. D’Amico AV, Chen MH, Oh-Ung J, et al.  Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int. J. Radiat. Oncol. Biol. Phys. 2002;54(2):436–441
  16. Pollack A, Zagars GK, Starkschall G, et al.  Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 2002;53(5):1097–1105
  17. Valicenti R, Lu J, Pilepich M, et al.  Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J. Clin. Oncol. 2000;18(14):2740–2746
  18. Dearnaley D, Aird E, Bidmead AM, et al.  High dose conformal radiotherapy in localised prostate cancer: the MRC RT01 randomised trial. Proc. ASCO. 2002;21:769
  19. Bolla M, Gonzalez D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 1997;337(5):295–300
  20. Pilepich MV, Winter K, John MJ, et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 2001;50(5):1243–1252
  21. Laverdiere J, Gomez JL, Cusan L, et al.  Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1997;37(2):247–252
  22. Hanks G, Lu J, Machtay M, Venkatesan V, Pinover W, Byhardt R, et al. Proc. of Am. Soc. Ther. Rad. Oncol. (ASTRO), RTOG Protocol 92-02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 2000;48:112
  23. Parker C, Dearnaley D. Re: all-cause mortality in randomized trials of cancer screening. J. Natl. Cancer Inst. 2002;94(11):861–862 discussion 865–6
  24. Kirk D. Re: a structured debate – immediate versus deferred androgen suppression in prostate cancer – evidence for deferred treatment. J. Urol. 2002;167(2 Pt-1):652; discussion 653
  25. Simon D, Charles MA, Nahoul K, et al.  Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J. Clin. Endocrinol. Metab. 1997;82(2):682–685
  26. Smith JC, Bennett S, Evans LM, et al.  The effects of induced hypogonadism on arterial stiffness, body composition, metabolic parameters in males with prostate cancer. J. Clin. Endocrinol. Metab. 2001;86(9):4261–4267
  27. Roach M, 3rd, Lu J, Lawton C, et al. A phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: preliminary analysis of RTOG 9413. Int J Radiat Oncol Biol Phys 2002
  28. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J. Natl. Cancer Inst. 2002;94(13):958–960
  29. Nicholson PW, Harland SJ. Survival prospects after screen-detection of prostate cancer. BJU Int. 2002;90(7):686–693
  30. D’Amico AV, Whittington R, Malkowicz SB, et al.  Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 1999;17(1):168–172
  31. Choo R, Klotz L, Danjoux C, et al.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J. Urol. 2002;167(4):1664–1669
  32. Kupelian PA, Elshaikh M, Reddy CA, et al.  Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J. Clin. Oncol. 2002;20(16):3376–3385
  33. D’Amico AV, Whittington R, Malkowicz SB, et al.  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95(2):281–286
  34. Vicini FA, Martinez A, Hanks G, et al.  An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer. 2002;95(10):2126–2135
  35. Schwartz K, Bunner S, Bearer R, et al.  Complications from treatment for prostate carcinoma among men in the Detroit area. Cancer. 2002;95(1):82–89
  36. Potosky AL, Legler J, Albertsen PC, et al.  Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J. Natl. Cancer Inst. 2000;92(19):1582–1592
  37. Madalinska JB, Essink-Bot ML, de Koning HJ, et al.  Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J. Clin. Oncol. 2001;19(6):1619–1628
  38. Choo CR, Danjoux C, Morton GC. Should pathological T3 and/or margin positive prostate cancer receive adjuvant therapy? A radiation oncologist’s view. Can. J. Urol. 2000;7(3):1043–1050
  39. Parker C, Warde P, Catton C. Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother. Oncol. 2001;61(2):107–116
  40. Bolla M, Collette L, Blank L, et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–106
  41. Thames HD, Withers HR, Peters LJ, et al.  Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int. J. Radiat. Oncol. Biol. Phys. 1982;8(2):219–226
  42. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1999;43(5):1095–1101
  43. Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low. Int. J. Radiat. Oncol. Biol. Phys. 2001;50(4):1021–1031
  44. King CR, Fowler JF. A simple analytic derivation suggests that prostate cancer α/β ratio is low. Int. J. Radiat. Oncol. Biol. Phys. 2001;51(1):213–214
  45. Sanchez-Nieto B, Nahum AE, Dearnaley DP. Individualization of dose prescription based on normal-tissue dose-volume and radiosensitivity data. Int. J. Radiat. Oncol. Biol. Phys. 2001;49(2):487–499
  46. Fiorino C, Cozzarini C, Vavassori V, et al.  Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother. Oncol. 2002;64(1):1

PII: S0305-7372(03)00070-7

doi: 10.1016/S0305-7372(03)00070-7

Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 161-169 , June 2003

Article Tools

* Image Usage & Resolution